Xylitol and cardiovascular risk: what the NIH-funded study shows

What the study did and what it found

The investigation combined three strands: a discovery analysis, a validation analysis, and an intervention plus mechanistic testing. In the discovery phase, researchers used untargeted metabolomics to examine overnight fasting plasma samples from 1,157 sequential stable subjects undergoing elective diagnostic cardiac evaluations. They identified circulating signals compatible with xylitol that correlated with future cardiovascular events over a three-year horizon. To confirm this association, they then employed targeted measurements of xylitol in an independent validation cohort of 2,149 participants, reinforcing the link between higher circulating xylitol and incident major adverse cardiovascular events (MACE).

Across these human analyses, the top third of participants by circulating xylitol had about a 50% higher risk of a cardiovascular event over three years compared with the bottom third. In numerical terms, the validated cohort yielded a hazard ratio of 1.57 (95% CI: 1.12–2.21) when comparing the highest to the lowest tertile. An important nuance is that the study also tracked how xylitol levels behaved after dietary exposure: in a small intervention, 10 healthy volunteers consumed a xylitol-sweetened beverage, and blood xylitol rose approximately 1,000-fold within 30 minutes and then returned to baseline within four to six hours. Across the study protocol, this time course helped investigators examine how dietary intake relates to observed circulating xylitol levels and their potential link to clotting processes.

Beyond the human analyses, the team conducted mechanistic studies in vitro and in vivo. When human platelets were exposed to higher xylitol levels, platelets showed increased sensitivity to clotting signals, similarly to prior observations with erythritol. In mouse models, xylitol exposure accelerated clot formation and thrombosis. Taken together, the researchers argued that elevated circulating xylitol could reflect a prothrombotic state or disease-related changes in metabolism, rather than a direct harmful effect of dietary xylitol itself.

The endogenous production caveat

A central interpretation emphasized by the researchers is that much of the circulating xylitol observed in the population appears to come from endogenous production, not directly from dietary intake. The study’s own messaging highlights that fasting xylitol levels are largely generated inside the body as part of normal metabolism, and the rapid post-prandial spike after a xylitol-rich drink returns to baseline within hours. This pattern suggests that the association between circulating xylitol and MACE risk may reflect broader metabolic health or disease states—such as diabetes, liver disease, or inflammation—rather than causation by dietary xylitol itself. As one critic noted in independent analysis, the plasma levels in observational cohorts can be viewed as readouts of endogenous production rather than food intake. This nuance matters for readers seeking practical dietary guidance: the study provides no evidence that dietary xylitol causes major cardiovascular events.

Revamping the FAQ around this point is prudent. Specifically, the strongest takeaway should be that endogenous production dominates fasting levels, and elevated xylitol may signal underlying metabolic conditions that themselves elevate cardiovascular risk. Consequently, readers should be cautious about inferring a direct causal link between consuming xylitol-containing products and heart attack or stroke from this study alone.

Mechanistic insights and limitations

The study combined isolated human platelets, platelet-rich plasma, whole-blood assays, and animal models to explore mechanisms by which xylitol might influence clotting. In mice, the prothrombotic effects were observed, but researchers caution that mice poorly absorb dietary xylitol, often necessitating injections to achieve measurable systemic levels. This exposure route differs from typical human dietary intake and does not faithfully mimic endogenous production, underscoring limits in translating animal findings to humans. Additionally, platelet-rich plasma uses higher-than-normal platelet concentrations than found in human blood, which can affect clotting readouts. Taken together, these translational gaps temper conclusions about how dietary xylitol might translate to human cardiovascular risk and emphasize that the in vivo clotting results are not directly applicable to everyday human exposure without further study.

Biochemically, xylitol is linked to the glucuronic acid pathway, and this pathway tends to be more active in certain disease states. The glucuronic acid pathway’s activity can rise in diabetes, liver disease, and systemic inflammation, potentially elevating endogenous xylitol independently of diet. While the study discusses these pathways, readers should understand that increased xylitol production could be a marker of metabolic stress rather than a causal factor in cardiovascular events. This mechanistic caveat helps explain why the observational association may reflect a larger metabolic context rather than a direct dietary effect.

Context: how this fits with other evidence

It’s important to situate these findings within the broader literature on sugar alcohols. The same research team previously explored erythritol and cardiovascular risk, and critics have pointed to similarities in study design and interpretation. While some evidence suggests cardiovascular or metabolic effects from sugar alcohols, this article emphasizes that much of the xylitol signal likely reflects endogenous production and metabolic status rather than dietary intake. Moreover, xylitol has well-established health benefits in other areas—most notably dental health and glycemic control in certain contexts—so readers should weigh potential risks against these benefits. The study’s design—spanning observational data, preclinical experiments, and an intervention—does not provide a definitive verdict on dietary xylitol safety, and the authors themselves call for further safety evaluations of sugar alcohols as a class.

What this means for consumers: practical guidance

Given the evidence, readers should understand that the strongest signal here concerns circulating xylitol and cardiovascular risk in a high-risk, metabolically heterogeneous population, not dietary xylitol intake per se. Practical guidance should be nuanced and actionable across different usage patterns:

• High-dose dietary products (for example, xylitol-sweetened beverages or large portions of foods) should be considered with caution, especially for individuals with cardiovascular risk factors or known metabolic diseases. Moderation is reasonable until more is known.
• Low-dose oral care products (toothpaste, mouthwash, dental gums) are very unlikely to pose a risk based on current evidence and are not something to abandon unless directed by a clinician.
• People with diabetes or metabolic syndrome may have a different endogenous xylitol production context. If you fall into this category, consult a healthcare provider for personalized guidance on xylitol-containing products.

The NIH and Cleveland Clinic communications emphasize that high levels of xylitol in a product could raise risk signals, but this does not imply that typical toothpaste use or small amounts in food are dangerous for all individuals. A clinician can help tailor decisions to individual risk factors and overall dietary patterns.

Study design notes, limitations, and disclosures

The study pooled data from a large pool of participants—more than 3,000 in total across analyses conducted in the United States and Europe. Discovery and validation cohorts comprised 1,157 and 2,149 individuals, respectively, all described as sequential stable subjects undergoing elective diagnostic cardiac evaluations, indicating a higher baseline cardiovascular risk than the general population. This limits how broadly the results can be generalized to healthy individuals without established risk factors. The authors also used a combination of observational data and mechanistic experiments to probe causality, but observational studies cannot establish causation on their own.

Funding for the work came from the National Institutes of Health (NHLBI) and the Office of Dietary Supplements, with additional support from the Deutsche Forschungsgemeinschaft and other sources. Disclosures note that Dr. Hazen is named as a co-inventor on pending and issued patents held by the Cleveland Clinic related to cardiovascular diagnostics and therapeutics, a potential conflict of interest that readers may want to consider when weighing conclusions.

In the conclusions, the authors indicate that the data do not demonstrate that dietary xylitol directly causes MACE; rather, they show associations between circulating xylitol and future cardiovascular events. Critics of the study design have argued that the same limitations seen in the erythritol literature apply here, and that the broader takeaway should be cautious about extrapolating dietary risk from circulating xylitol levels. Consequently, the article’s most defensible message is that endogenous xylitol production tracks with metabolic states associated with cardiovascular risk, not that consuming xylitol-containing foods or products definitively harms heart health.

Bottom line for readers

The NIH-funded work adds to a growing conversation about sugar alcohols and cardiovascular risk, but it does not prove that dietary xylitol harms heart health. Elevated circulating xylitol appears to be more closely tied to endogenous production and metabolic health than to what people eat or drink. Until further controlled trials specifically addressing dietary exposure are conducted, use xylitol-containing products as you would other sugar substitutes, balancing potential metabolic considerations with recognized benefits in dental health and glycemic contexts. If you have cardiovascular risk factors or metabolic disease, discuss xylitol use with your healthcare provider to personalize guidance.

References and sources

Xylitol is prothrombotic and associated with cardiovascular risk. Witkowski M, Nemet I, Li XS, Wilcox J, Ferrell M, Alamri H, Gupta N, Wang Z, Tang WHW, Hazen SL. Eur Heart J. 2024 Jun 6:ehae244. doi: 10.1093/eurheartj/ehae244.

The study combined discovery analyses, targeted LC-MS/MS validation for xylitol, mechanistic experiments in platelets and animals, and an intervention in healthy volunteers (n = 10) to assess the effects of xylitol consumption on platelet function.

Funding and disclosures include NIH NHLBI support and Hazen’s status as co-inventor on Cleveland Clinic patents related to cardiovascular diagnostics and therapeutics.